Drug Development
BAY 12-9566 is toxic when combined with etoposide and carboplatin
Published in Blood Weekly, December 8th, 2005
According to a study from the United States, "matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that degrade the extracellular matrix during the processes of invasion, metastasis and angiogenesis. BAY is a selective, non-peptidic biphenyl inhibitor of MMPs, with nanomolar inhibitory activity against MMP-2, -3 and -9, and anti-invasive, anti-metastatic and antiangiogenic activity in a variety of tumor models."
"This phase I study of oral BAY was conducted to evaluate the safety and pharmacokinetics of BAY when administered in combination with etoposide (VP-16) or...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2005-12-08)
More Articles from Blood Weekly
- Blood Safety
Empirical model investigates the determinants of a safe and sufficient blood supply - Bone Fracture
Osteoblastic cells mobilized and recruited from remote bone marrow sites for fracture healing - Stem Cell Research
Increased circulating endothelial progenitor cells associated with survival in acute lung injury - Surgery
Blood transfusions performed after musculoskeletal tumor surgery - Tissue Engineering
Collagen-modified PLGA scaffold developed for tissue engineering of the esophagus - Acute Myeloid Leukemia
Clofarabine's duration of response improves outcome for elderly AML patients - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
